Praluent Cost in Maine 2026: Prices, Insurance, Medicaid, and Compounded Options

What Is Alirocumab and Why Does the Price Matter?

Alirocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. Blocking PCSK9 allows those receptors to recycle and clear more LDL-cholesterol from the bloodstream. The FDA approved alirocumab (brand name Praluent) in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. The FDA prescribing information is available at the FDA accessdata portal.

The drug's list price has historically been a barrier. At $580 per month, a year of therapy exceeds $6,900 before insurance adjustments. For Maine residents managing cardiovascular risk, understanding every available cost-reduction pathway is essential. The American College of Cardiology notes that cost and prior authorization requirements remain the leading reasons PCSK9 inhibitors are discontinued within the first year.

Alirocumab is given as a subcutaneous injection of 75 mg every two weeks, with dose escalation to 150 mg every two weeks if the LDL-C response is insufficient at 8 weeks. The dosing rationale and pharmacokinetic data are described in the FDA label.

The Clinical Evidence Behind Alirocumab

Alirocumab's price is anchored to an impressive evidence base. The landmark ODYSSEY OUTCOMES trial enrolled 18,924 patients with a recent acute coronary syndrome and followed them for a median of 2.8 years. Patients randomized to alirocumab 75-150 mg every two weeks experienced a 15% relative reduction in the composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, and unstable angina requiring hospitalization, compared with placebo (hazard ratio 0.85; 95% CI 0.78-0.93; P<0.001). ODYSSEY OUTCOMES is published in the New England Journal of Medicine.

The absolute risk reduction was 1.6 percentage points over the trial period, translating to a number-needed-to-treat of roughly 63 over 2.8 years to prevent one major event. In the prespecified subgroup of patients with baseline LDL-C at or above 100 mg/dL, the benefit was larger: a 24% relative risk reduction. Full subgroup analyses are available in the NEJM publication.

Beyond ODYSSEY OUTCOMES, the ODYSSEY FH I and FH II trials demonstrated that alirocumab reduced LDL-C by approximately 49% from baseline in patients with heterozygous familial hypercholesterolemia who were already on maximally tolerated statin therapy. PubMed hosts the FH I and FH II trial data.

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states that in patients with very high-risk ASCVD and LDL-C persistently at or above 70 mg/dL on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended (Class I, Level of Evidence: A). The 2022 ACC/AHA cholesterol guideline update is accessible through the AHA Journals.

The guideline writing committee wrote directly: "For patients with clinical ASCVD who are at very high risk, it is recommended to add a PCSK9 inhibitor to maximally tolerated statin therapy and ezetimibe if LDL-C remains 70 mg/dL or higher." That language provides Maine clinicians and insurers a clear threshold for coverage justification.

Praluent List Price vs. What Maine Patients Actually Pay

The manufacturer's list price for Praluent in 2026 sits at approximately $580 per month, the same at Maine retail chains including Walgreens, CVS, and independent pharmacies. That figure reflects the wholesale acquisition cost and does not account for insurer rebates, copay assistance, or formulary tiers. The FDA's approved drug database confirms the product and indication.

Cash-pay patients without any coverage or assistance face the full $580 monthly charge. That is the ceiling, not the floor.

For patients with commercial insurance, the real out-of-pocket cost depends on:

1. Whether the plan includes alirocumab on its formulary at all.
2. The tier placement (specialty tier copays typically run $100-$300 per month before deductible).
3. Whether prior authorization criteria are satisfied.
4. Eligibility for the Regeneron/Sanofi savings card, which can reduce the patient share to $0 for commercially insured individuals.

Patients enrolled in Maine Medicaid (MaineCare) or Medicare Part D face entirely different cost structures, covered in the sections below.

Maine Medicaid (MaineCare) Coverage for Praluent

MaineCare covers alirocumab, but a prior authorization (PA) is required. The two primary qualifying diagnoses are heterozygous familial hypercholesterolemia and established ASCVD, provided the patient is also on maximally tolerated statin therapy and LDL-C remains above guideline thresholds. The Medicaid drug policy framework is governed by CMS guidance documented on the CMS/Medicaid site.

PA approval typically requires documentation of:

• A confirmed diagnosis of HeFH or an ASCVD event (myocardial infarction, stroke, peripheral artery disease, or unstable angina requiring hospitalization).
• Current statin therapy at maximally tolerated dose, plus ezetimibe if tolerated.
• A recent LDL-C lab value above the plan's threshold (commonly 70 mg/dL for ASCVD, 100 mg/dL for HeFH without ASCVD).
• A prescribing physician attestation that the patient has been counseled on lifestyle modification.

Once PA is granted, MaineCare patients typically pay little to nothing for the drug itself under the pharmacy benefit. The PA renewal period is usually 12 months, and the prescriber must resubmit documentation with updated labs at renewal. Denials can be appealed; the ACC/AHA Class I recommendation for very-high-risk ASCVD patients is frequently cited successfully in appeals. The ACC provides guidance on PCSK9 inhibitor access appeals.

Which Commercial Insurance Plans Cover Praluent in Maine?

Most large commercial carriers operating in Maine, including Anthem BlueCross BlueShield of Maine, Aetna, Cigna, Harvard Pilgrim, and Tufts Health Plan, include alirocumab on their specialty formularies subject to PA and step therapy requirements. CMS outlines the framework for formulary exceptions and specialty tier drugs.

Step therapy requirements commonly mandate that the patient must have tried and failed (or have a contraindication to) at least two statins at maximally tolerated doses, and often ezetimibe as well, before PCSK9 inhibitor coverage is approved. Some plans also require documented LDL-C values on therapy to confirm inadequate response.

The practical implication for Maine patients: work with your prescribing cardiologist or internist to compile a complete medication history, lab results, and any records of statin-associated side effects before submitting the PA. Incomplete submissions are the most common reason for initial denial.

Specialty tier cost sharing for Praluent on commercial plans in Maine ranges widely. After deductible, expect $80-$200 per injection fill (a 28-day or 60-day supply, depending on dose) without additional assistance. With the manufacturer copay card, commercially insured patients may reduce this to $0. GoodRx and similar platforms also aggregate real-time pharmacy pricing, though their discount cards are generally not combinable with insurance.

The Regeneron / Sanofi Praluent Savings Card: How It Works in Maine

Regeneron and Sanofi offer a manufacturer copay savings program for commercially insured patients who are not enrolled in any government-funded health plan (Medicare, Medicaid, TRICARE, or any other federal or state program). Eligible patients can pay as little as $0 per month with a maximum annual savings cap set by the manufacturer.

Eligibility rules for the 2026 card include:

• US resident with valid commercial insurance covering Praluent.
• Not enrolled in Medicare Part A, B, or D, or any state Medicaid program.
• Prescription written by a licensed US prescriber.

Maine patients can enroll online through the Praluent patient support site or by calling the manufacturer's patient services number. The savings card is applied at the pharmacy at the point of sale. FDA-approved labeling and patient resources for Praluent are listed through the FDA's drug database.

Patients who do not qualify for the savings card because of government insurance should ask their provider about patient assistance programs (PAPs), which Sanofi operates separately and which may provide the drug free of charge to qualifying low-income patients.

Compounded Alirocumab in Maine: Legality and Practical Access

Compounded alirocumab is legal in Maine when prepared and dispensed by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed Maine provider. The FDA does not classify alirocumab on the list of drugs that may not be compounded under section 503A of the Federal Food, Drug, and Cosmetic Act. FDA's compounding guidance is published on the FDA regulatory guidance page.

A 503A pharmacy must compound on a patient-by-patient basis rather than in large bulk batches. This means the prescriber must write a prescription for a specific patient, and the pharmacy fills it individually rather than stocking pre-made units. The FDA's 503A vs. 503B framework is explained in the agency's compounding FAQ.

The cost difference is substantial. Compounded alirocumab from select 503A pharmacies may be available for as little as $0 per month to the patient, compared with the $580 list price for brand Praluent. This pricing variation reflects the compounding pharmacy's cost structure and any membership or subscription models they operate, not a federal subsidy. Pharmacy compounding oversight is also addressed through state boards; Maine's Board of Pharmacy operates under state statute.

Clinicians considering compounded alirocumab for Maine patients should verify three things before writing the prescription: (1) the pharmacy holds a current Maine 503A license, (2) the formulation uses pharmaceutical-grade alirocumab active pharmaceutical ingredient with documented purity testing, and (3) the patient understands that compounded products lack FDA approval for the specific formulation and are not interchangeable with the FDA-approved Praluent product.

Patients who have already failed or cannot access brand Praluent, who are not covered by commercial insurance or government programs, and who meet clinical criteria represent the strongest candidates for this pathway. The prescribing standard of care remains the same regardless of which product is dispensed: confirmed diagnosis, maximally tolerated statin background therapy, and LDL-C monitoring at 4-8 weeks after initiation. Monitoring recommendations are consistent with the ACC/AHA 2022 cholesterol guideline.

Telehealth Prescribing of Praluent in Maine

Maine law permits telehealth prescribing of alirocumab for established patients with documented cardiovascular diagnoses. A prescribing clinician licensed in Maine may initiate or continue a Praluent prescription via a synchronous audio-video telehealth visit, provided the prescriber has reviewed relevant diagnostic history, current medications, and recent LDL-C laboratory data. Maine's telehealth prescribing standards are governed by state statute and align with post-pandemic federal flexibilities under CMS guidance.

For new patients seeking alirocumab through telehealth, the prescriber must be able to form a valid provider-patient relationship under Maine law, which requires at minimum a synchronous real-time interaction sufficient to complete a clinical evaluation. Prescribing based solely on a patient-completed questionnaire does not meet Maine's standard for a controlled or specialty injectable. CMS telehealth policy updates affecting Maine Medicare patients are tracked on the CMS telehealth page.

HealthRX's licensed Maine providers can evaluate cardiovascular risk, review prior statin therapy documentation, and manage the prior authorization process for both brand and compounded alirocumab during a telehealth visit. Lab work must be completed at a facility or mobile draw site in Maine before the prescription is finalized.

How Alirocumab Is Used Clinically: Dose, Monitoring, and Side Effects

Alirocumab is started at 75 mg subcutaneously every two weeks. If the LDL-C response is inadequate at the 8-week mark, the dose is increased to 150 mg every two weeks. The injection is delivered via a single-use prefilled pen or syringe to the abdomen, upper arm, or thigh. Patients or caregivers can self-administer after training. Dosing and administration details are in the FDA-approved prescribing information.

LDL-C should be measured 4-8 weeks after initiation and after any dose change to confirm response. Alirocumab can reduce LDL-C by 45-60% from baseline on top of statin therapy. The ODYSSEY LONG TERM trial (N=2,341) confirmed sustained LDL-C reductions of approximately 61% from baseline at 78 weeks.

Common adverse effects include injection-site reactions (erythema, itching, bruising) occurring in approximately 7% of patients versus 5% on placebo in clinical trials. Nasopharyngitis was reported in roughly 11% of alirocumab-treated patients in ODYSSEY OUTCOMES. Neurocognitive events were numerically balanced between alirocumab and placebo arms across trials, and no causal relationship has been established. Safety data are summarized in the ODYSSEY OUTCOMES supplementary material and FDA label.

The Cheapest Path to Alirocumab in Maine: A Cost Comparison

Understanding the full range of costs helps Maine patients and their providers choose the most accessible route.

| Pathway | Estimated Monthly Cost (2026) | |---|---| | Cash pay (brand Praluent) | ~$580 | | Commercial insurance, specialty tier | $80-$300 (before savings card) | | Commercial insurance + manufacturer savings card | $0 (commercially insured, non-government plan) | | Maine Medicaid (MaineCare), PA approved | $0-minimal copay | | Medicare Part D (no LIS) | Varies; typically $100-$350 after deductible | | Medicare Part D (Low Income Subsidy) | $0-$12 | | Compounded alirocumab, 503A pharmacy | May be $0/month (pharmacy-dependent) | | Sanofi Patient Assistance Program | $0 (income-qualified, uninsured or underinsured) |

The Sanofi Insulins U.S. Patient Assistance Foundation and the broader Sanofi Patient Connection program provide brand Praluent at no charge to patients who are uninsured or underinsured and meet income criteria, generally at or below 400% of the federal poverty level. Applications require proof of income and a prescriber signature. Patient assistance program details align with guidance from NeedyMeds and manufacturer disclosures tracked by the FDA.

For most uninsured Maine residents who do not qualify for MaineCare, the realistic options are the manufacturer PAP or compounded alirocumab from a licensed 503A pharmacy. Both require a valid prescription from a Maine-licensed provider.

Prior Authorization: How to Improve Approval Odds in Maine

Prior authorization denials for PCSK9 inhibitors occur frequently on first submission. A 2019 analysis published in Circulation found that only 54% of PCSK9 inhibitor PA requests received approval on the first attempt, and a significant proportion of denied patients never reapplied. That analysis is available through AHA Journals.

Strategies that improve first-pass approval rates in Maine:

First, submit the PA with a complete clinical summary that specifically cites the ACC/AHA 2022 Class I recommendation and the patient's LDL-C value relative to the 70 mg/dL threshold. Second, document each statin the patient has tried, the dose, the duration, and the reason for discontinuation or dose limitation (myopathy, elevated transaminases, patient preference). Third, include ezetimibe trial documentation; most Maine commercial plans require it. Fourth, attach the most recent LDL-C result dated within 90 days. PA best practices are outlined in the ACC's quality improvement guidance.

If an initial PA is denied, Maine law provides patients the right to an internal appeal followed by an independent external review. The external review process is administered by the Maine Bureau of Insurance and is typically resolved within 45 days for non-urgent cases or 72 hours for expedited reviews. Maine Bureau of Insurance guidance on external review is accessible through the state's official insurance regulatory portal.

LDL-C Targets and Who Qualifies for Alirocumab in Maine

Not every patient with elevated LDL-C meets the clinical threshold for alirocumab. The 2022 ACC/AHA guideline reserves PCSK9 inhibitors for specific high-risk groups where statin plus ezetimibe therapy has proven insufficient. The full guideline text is at AHA Journals.

Qualifying categories include:

• Very high-risk ASCVD: LDL-C at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe.
• Heterozygous FH without ASCVD: LDL-C at or above 100 mg/dL despite maximally tolerated statin plus ezetimibe.
• Statin intolerance: Documented inability to tolerate any statin at any dose, with LDL-C above guideline thresholds.

Homozygous familial hypercholesterolemia is generally treated with different agents (such as evolocumab or lomitapide), as PCSK9 inhibitor efficacy in HoFH is limited due to the underlying genetic mechanism. The distinction between HeFH and HoFH treatment is addressed in the ACC/AHA guideline and supporting literature.

A fasting lipid panel within the prior 90 days is the minimum lab requirement before initiating alirocumab. Many Maine providers also obtain a comprehensive metabolic panel to document baseline liver function and a creatine kinase level to establish a statin myopathy baseline.